Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plexxikon has initiated dosing in the first of two Phase I clinical trials, which will evaluate PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis (RA).
Subscribe to our email newsletter
The first Phase I clinical trial is a single-ascending dose study in 32 healthy volunteers, while the second trial is a multiple-ascending dose study in 32 RA patients that will be initiated once the first cohort of healthy volunteers has been cleared for safety.
Preclinical studies demonstrated that PLX5622 reduced inflammation, reduced cartilage damage and prevented bone resorption.
Plexxikon said PLX5622 also significantly improved grip strength and clinical scores, as well as improved knee joint range-of-motion scores.